Education
About Us
Working with TipRanks
Follow Us
Bruker Corp (BRKR)
NASDAQ:BRKR
BRKR Stock Chart & Stats
$48.03
-$0.59(-0.96%)
At close: 4:00 PM EST
$48.03
-$0.59(-0.96%)
Day’s Range― - ―
52-Week Range$28.53 - $64.64
Previous CloseN/A
Volume340.61K
Average Volume (3M)2.86M
Market Cap
$7.18B
Enterprise Value$6.71B
Total Cash (Recent Filing)$295.00M
Total Debt (Recent Filing)$2.05B
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Feb 17, 2026EPS Estimate
0.65Last Dividend Ex-Date
Dec 08, 2025Dividend Yield0.42%
Share Statistics
EPS (TTM)0.45
Shares Outstanding151,941,150
10 Day Avg. Volume2,512,856
30 Day Avg. Volume2,859,045
Financial Highlights & Ratios
PEG Ratio-1.04
Price to Book (P/B)4.90
Price to Sales (P/S)2.59
P/FCF Ratio64.22
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit4.12
Enterprise Value/Ebitda23.24
Forecast
1Y Price Target
$47.17Price Target Upside-1.79% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.88
Revenue Forecast (FY)$3.42B
Bulls Say, Bears Say
Bulls Say
Cost Savings InitiativeManagement's new $100-120M run rate cost-savings initiative should drive $30M of savings in FY25 and at least 300 bps of operating margin expansion in FY26.
Earnings And ValuationBRKR remains attractive at current valuations, trading at a lower EV/EBITDA compared to large cap tools peers.
Product LeadershipManagement remains confident in its protein product leadership and position for a post-genomics environment.
Bears Say
Bookings DurabilityManagement's hesitancy to indicate that the 3Q booking upturn was durable held back the stock.
Covenant RiskA key concern for Bruker Corporation shares has been covenant risk due to increased leverage following an acquisition and pressures on end-markets.
Market Recovery DependenceThe recovery in BRKR shares is still dependent on the macro and more importantly the outlook for academic markets in US and China.
Bruker News
BRKR FAQ
What was Bruker Corp’s price range in the past 12 months?
Bruker Corp lowest stock price was $28.53 and its highest was $64.64 in the past 12 months.
What is Bruker Corp’s market cap?
Bruker Corp’s market cap is $7.18B.
When is Bruker Corp’s upcoming earnings report date?
Bruker Corp’s upcoming earnings report date is Feb 17, 2026 which is in 71 days.
How were Bruker Corp’s earnings last quarter?
Bruker Corp released its earnings results on Nov 03, 2025. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.354 by $0.096.
Is Bruker Corp overvalued?
According to Wall Street analysts Bruker Corp’s price is currently Overvalued.
Does Bruker Corp pay dividends?
Bruker Corp pays a Quarterly dividend of $0.05 which represents an annual dividend yield of 0.42%. See more information on Bruker Corp dividends here
What is Bruker Corp’s EPS estimate?
Bruker Corp’s EPS estimate is 0.65.
How many shares outstanding does Bruker Corp have?
Bruker Corp has 151,941,150 shares outstanding.
What happened to Bruker Corp’s price movement after its last earnings report?
Bruker Corp reported an EPS of $0.45 in its last earnings report, beating expectations of $0.354. Following the earnings report the stock price went down -0.591%.
Which hedge fund is a major shareholder of Bruker Corp?
Currently, no hedge funds are holding shares in BRKR
Bruker Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.17 (-1.79% Downside)
$47.17 (-1.79% Downside)
Hedge Fund Trend
Increased
By 173.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $600.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.26%
12-Months-Change
Fundamentals
Return on Equity
-0.99%
Trailing 12-Months
Asset Growth
5.27%
Trailing 12-Months
Company Description
Bruker Corp
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
BRKR Company Deck
BRKR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were positive developments such as improved order performance in Q3, successful cost-saving initiatives, and growth in certain segments like diagnostics and spatial biology, these were counterbalanced by revenue declines and operational challenges. The company faces ongoing difficulties in the U.S. academic and government markets, and some revenue is being deferred to the next fiscal year.View all BRKR earnings summariesBRKR Stock 12 Month Forecast
Average Price Target
$47.17
▼(-1.79% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---